Baird Medical Advances Microwave Ablation Training at Leading U.S. Thyroid Centers

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) has successfully conducted physician training programs for its Microwave Ablation (MWA) technology at leading U.S. medical centers. The company hosted intensive training sessions at Tulane University and Columbia University to enhance clinical proficiency in thyroid nodule treatment.

At Tulane University, Dr. Emad Kandil led training through five live cases for specialists from multiple institutions. At Columbia University, Dr. Jennifer Kuo conducted specialized courses in May and August, demonstrating successful ablation of large thyroid nodules. The initiative aims to establish MWA as a leading treatment option for thyroid disease.

Positive

• Successful training programs established at prestigious institutions (Tulane and Columbia University)
• Demonstrated effectiveness in treating large thyroid nodules
• Expanding network of trained physicians from major healthcare institutions

Negative

• None.

NEW YORK, Oct. 1, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a global leader in minimally invasive Microwave Ablation (MWA) technology, highlighted its recent series of sponsored physician training programs hosted at premier U.S. academic medical centers. Over the past several months, these intensive, hands-on courses at Tulane University and Columbia University have advanced the clinical proficiency of physicians in the use of MWA for thyroid nodule treatment.

These initiatives underscore Baird Medical's commitment to fostering clinical excellence and ensuring the safe, effective adoption of its MWA technology. In May, a session at Tulane University led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery, provided immersive training through five live cases for specialists from The George Washington University, UT Health Houston, and Texas Tech University Health Sciences Center. Concurrently, Baird Medical sponsored two specialized courses at Columbia University in May and August, where Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program, trained physicians from UCSF Health and Dignity Health. These sessions demonstrated the profound clinical impact and efficiency of Baird's system, highlighted by the successful ablation of large thyroid nodules.

"Our mission extends beyond developing innovative technology; it includes ensuring that clinicians are expertly trained to deliver the best possible patient outcomes," said Haimei Wu, Chairwoman of Baird Medical. "These collaborations with world-class institutions are fundamental to our commitment to setting the highest standard of care in the field."

Baird Medical remains dedicated to expanding its educational initiatives and partnering with key opinion leaders to further establish MWA as a leading treatment option for patients with thyroid disease.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-advances-microwave-ablation-training-at-leading-us-thyroid-centers-302572443.html

SOURCE BDMD

FAQ

What medical centers are partnering with Baird Medical (BDMD) for MWA training?

Baird Medical is conducting training programs at Tulane University and Columbia University, with participating physicians from institutions including UCSF Health, Dignity Health, The George Washington University, UT Health Houston, and Texas Tech University.

Who are the key physicians leading Baird Medical's MWA training programs?

The training programs are led by Dr. Emad Kandil, Professor and Ellis Hanna Chair in Surgery at Tulane University, and Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program at Columbia University.

What is the purpose of Baird Medical's MWA training initiative?

The initiative aims to advance clinical proficiency in using Microwave Ablation (MWA) technology for thyroid nodule treatment, ensure safe and effective adoption of the technology, and establish MWA as a leading treatment option for thyroid disease.

How many live cases were performed during the Baird Medical training at Tulane University?

The training session at Tulane University included five live cases demonstrating the MWA technology for thyroid nodule treatment.